Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects

Psychopharmacology

Volumn 177, Issue 4, 2005, Pages 357-365

  Chalon, Stephan ^b   Pereira, Alvaro ^a   Lainey, Eric ^c   Vandenhende, François ^a   Watkin, John G ^b   Staner, Luc ^d   Granier, Luc André ^a  

^a Eli Lilly Benelux   (Belgium)

^b ELI LILLY AND COMPANY   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Centre Hospitalier de Rouffach   (France)

Author keywords

Desipramine; Duloxetine; Polysomnography; REM sleep; Sleep

Indexed keywords

DESIPRAMINE; DULOXETINE; ANTIDEPRESSANT AGENT; NORADRENALIN; SEROTONIN; THIOPHENE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ELECTROENCEPHALOGRAPHY; HUMAN; INSOMNIA; MALE; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP; SLEEP DISORDER; STEADY STATE; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; METABOLISM; SLEEP STAGE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CROSS-OVER STUDIES; DESIPRAMINE; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; NOREPINEPHRINE; POLYSOMNOGRAPHY; QUESTIONNAIRES; SEROTONIN; SLEEP; SLEEP STAGES; THIOPHENES;

EID: 13644264838     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1961-0     Document Type: Article

References (63)

1. Bixler EO, Kales A, Soldatos CR, Kales JD, Healey S (1979) Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 136:1257-1262
2. Breslau N, Roth T, Rosenthal L, Andreski P (1996) Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 39:411-418
3. Brezinova V, Adam K, Chapman K, Oswald I, Thomson J (1977) Viloxazine, sleep, and subjective feelings. Psychopharmacology 55:121-128
4. Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Leger D, Linkowski P, Mendelson WB, Racagni G, Saletu B, Sharpley AL, Turek F, Van Cauter E, Mendlewicz J (2000) Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology 42:107-119
5. Buysse DJ, Frank E, Lowe KK, Cherry CR, Kupfer DJ (1997) Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression. Biol Psychiatry 41:406-418
6. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880
7. Chalon S, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ (2004) Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 28:1685-1693
8. Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME (1999) The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 60:142-156
9. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002a) Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315
10. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA (2002b) Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383
11. Engleman EA, Perry KW, Mayle DA, Wong DT (1995) Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsycho-pharmacology 12:287-295
12. Farina B, Della M, Mennuni G, Mazza S, De Risio S, Di Giannantonio M (2002) The effects of reboxetine on human sleep architecture in depression: preliminary results. J Affect Disord 71:273-275
13. Feuillade P, Pringuey D, Belugou JL, Robert P, Darcourt G (1992) Trimipramine: acute and lasting effects on sleep in healthy and major depressive subjects. J Affect Disord 24:135-145
14. Giles DE, Jarrett RB, Roffwarg HP, Rush AJ (1987) Reduced rapid eye movement latency. A predictor of recurrence in depression. Neuropsychopharmacology 1:33-39
15. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ (1997) A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58:185-192
16. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63:225-231
17. Gumnick JF, Nemeroff CB (2000) Problems with currently available antidepressants. J Clin Psychiatry 61(Suppl 10):5-15
18. Gursky JT, Krahn LE (2000) The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 8:298-306
19. Hartmann E, Cravens J (1973) The effects of long-term administration of psychotropic drugs on human sleep. III. The effects of amitriptyline. Psychopharmacologia 33:185-202
20. Kennedy GJ, Kelman HR, Thomas C (1991) Persistence and remission of depressive symptoms in late life. Am J Psychiatry 148:174-178
21. Kihara T, Ikeda M (1995) Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272:177-183
22. Kupfer DJ, Foster FG (1972) Interval between onset of sleep and rapid-eye-movement sleep as an indicator of depression. Lancet 2:684-686
23. Kupfer DJ, Frank E (1984) The relationship of EEG sleep to vital depression. J Affect Disord 7:249-263
24. Kupfer DJ, Foster FG, Reich L, Thompson SK, Weiss B (1976) EEG sleep changes as predictors hi depression. Am J Psychiatry 133:622-626
25. Kupfer DJ, Foster FG, Coble P, McPartland RJ, Ulrich RF (1978) The application of EEG sleep for the differential diagnosis of affective disorders. Am J Psychiatry 135:69-74
26. Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski VJ, Wilson MJ, McEachran AB (1991) Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 29:23-40
27. Kupfer DJ, Pollock BG, Perel JM, Miewald JM, Grochocinski VJ, Ehlers CL (1994) Effect of pulse loading with clomipramine on EEG sleep. Psychiatry Res 54:161-175
28. Le Bon O, Staner L, Murphy JR, Hoffmann G, Pull CH, Pelc I (1997) Critical analysis of the theories advanced to explain short REM sleep latencies and other sleep anomalies in several psychiatric conditions. J Psychiatr Res 31:433-450
29. Luthringer R, Toussaint M, Schaltenbrand N, Bailey P, Danjou PH, Hackett D, Guichoux JY, Macher JP (1996) A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 32:637-646
30. McCarley RW (1982) REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry 139:565-570
31. Mellinger GD, Balter MB, Uhlenhuth EH (1985) Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 42:225-232
32. Mendlewicz J, Kerkhofs M (1991) Sleep electroencephalography in depressive illness. A collaborative study by the World Health Organization. Br J Psychiatry 159:505-509
33. Mendlewicz J, Kempenaers C, de Maertelaer V (1991) Sleep EEG and amitryptiline treatment in depressed inpatients. Biol Psychiatry 30:691-702
34. Nelson JC (1998) Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety 7(Suppl 1):5-6
35. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307
36. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132
37. Nicholson AN, Pascoe PA (1986) 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology 25:1079-1083
38. Nicholson AN, Pascoe PA (1991) Monoaminergic transmission and sleep in man. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishers, Petersfield, pp 215-226
39. Nowell PD, Buysse DJ (2001) Treatment of insomnia in patients with mood disorders. Depress Anxiety 14:7-18
40. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322
41. Parrott AC, Hindmarch I (1980) The leeds sleep evaluation questionnaire in psychopharmacological investigations - a review. Psychopharmacology 71:173-179
42. Perils ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ (1997) Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42:209-212
43. Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Brain Information Service Brain Research Institute, University of California Los Angeles
44. Reynolds CF III, Kupfer DJ (1987) Sleep research in affective illness: state of the art circa 1987. Sleep 10:199-215
45. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR (1991) Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14:439-447
46. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R (1997) Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 58:348-350
47. Schatzberg AF (1999) Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 60(Suppl 4):14-21
48. Schlosser R, Roschke J, Rossbach W, Benkert O (1998) Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 8:273-278
49. Seeman R (1993) Receptor tables, volume 2: dissociation constants for neuroreceptors and transporters. SZ Research, Toronto
50. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K (1992) Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161:562-565
51. Sharma A, Goldberg MJ, Cerimele BJ (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161-167
52. Shipley JE, Kupfer DJ, Griffin SJ, Dealy RS, Coble PA, McEachran AB, Grochocinski VJ, Ulrich R, Perel JM (1985) Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients. Psychopharmacology 85:14-22
53. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a metaanalysis. Br J Psychiatry 180:396-404
54. Staner L, Luthringer R, Macher J-P (1999) Effects of antidepressant drugs on sleep EEG in patients with major depression: mechanisms and therapeutic implications. CNS Drugs 11:49-60
55. Steiger A (1988) Effects of clomipramine on sleep EEG and nocturnal penile tumescence: a long-term study in a healthy man. J Clin Psychopharmacol 8:349-354
56. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241
57. Thase ME, Detke MJ, Joliat M, Lu Y (2003) Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Presented at the 156th Annual Meeting of the American Psychiatric Association, 22 May 2003
58. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P (2001) Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24:511-521
59. Van Bemmel AL, Vermeeren MT, Ruigt G, Sennef C (1999) The acute effects of the noradrenaline reuptake inhibitor Org 4428 on EEG sleep in healthy volunteers. Neuropsychobiology 40:107-114
60. Vasar V, Appelberg B, Rimon R, Selvaratnam J (1994) The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers. Int Clin Psychopharmacol 9:203-206
61. Vogel GW, Buffenstein A, Minter K, Hennessey A (1990) Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev 14:49-63
62. Winokur A, Reynolds CF III (1994) Overview of effects of antidepressant therapies on sleep. Primary Psychiatry 1:22-27
63. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP (2001) Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 14:19-28